Daxdilimab Improves Disease Activity in Refractory Discoid Lupus
A Phase 2 trial found daxdilimab improved disease activity in patients with treatment-refractory discoid lupus erythematosus, a hard-to-treat scarring autoimmune dermatosis.
Topic
Topic
A Phase 2 trial found daxdilimab improved disease activity in patients with treatment-refractory discoid lupus erythematosus, a hard-to-treat scarring autoimmune dermatosis.